TY - T1的睡眠呼吸暂停患者的癌症风险附着后5年CPAP疗法JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01935 -2021欧元SP - 2101935 AU Justeau格雷戈勒AU -贝利Sebastien AU - Gerves-Pinquie,克洛艾盟——Trzepizur Wojciech盟——Meslier妮可AU - Goupil,弗朗索瓦•AU - Pigeanne蒂埃里盟——Launois Sandrine盟——Leclair-Visonneau劳伦AU -马森,菲利普盟——Bizieux-Thaminy Acya盟——Racineux jean - louis盟——同时,大卫盟——Gagnadoux Frederic A2 - Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/08/12/13993003.01935 - 2021. -抽象N2 -背景越来越多的证据表明,阻塞性睡眠呼吸暂停(OSA)导致癌症的风险;然而,有限的数据可用的影响持续正压通气(CPAP)治疗癌症发病率。我们旨在确定坚持CPAP疗法与所有癌症发病率的减少而non-adherent阻塞性睡眠呼吸暂停综合症患者。方法研究依赖于数据收集的多中心研究支付de la卢瓦尔睡眠组,与卫生行政数据,如确定最近诊断为癌症。我们包括规定CPAP对阻塞性睡眠呼吸暂停综合症的病人,没有历史的癌症诊断睡眠研究之前或期间的第一年CPAP。记录患者CPAP每晚至少使用4 h被定义为附着。那些停止或晚上使用CPAP少于4 h non-adherent组构成。治疗的倾向评分逆概率权重分析评估CPAP依从性对癌症风险的影响。结果值(内部四分位范围)后随访5.4(3.1 - -8.0)年,437(9.7%)的4499个病人患了癌症,194年(10.7%)non-adherent组(n = 1817)和243年(9.1%)附着患者(n = 2682)。最后加权模型显示没有明显的CPAP依从性对全因癌症风险的影响(子分布风险比(95%置信区间)):0.94 (0.78; 1.14]).Conclusions Adherence to CPAP therapy in OSA patients was not associated with a reduction in all-cancer incidence. Whether adherent CPAP therapy of OSA might reduce the risk of specific cancer sites should be further evaluated.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Grégoire Justeau has nothing to disclose.Conflict of interest: S. Bailly reports Consulting fees for methodology and statistical analyses from ISRS Pays de la Loire, outside the submitted work.Conflict of interest: Chloé Gervès-Pinquié has nothing to disclose.Conflict of interest: Wojciech Trzepizur has nothing to disclose.Conflict of interest: Nicole Meslier has nothing to disclose.Conflict of interest: François Goupil has nothing to disclose.Conflict of interest: Thierry Pigeanne has nothing to disclose.Conflict of interest: Sandrine Launois has nothing to disclose.Conflict of interest: Laurene Leclair-Visonneau has nothing to disclose.Conflict of interest: Philippe Masson has nothing to disclose.Conflict of interest: Acya Bizieux-Thaminy has nothing to disclose.Conflict of interest: Jean-Louis Racineux has nothing to disclose.Conflict of interest: D. Gozal reports NIH grants outside the submitted work. All other authors have nothing to disclose.Conflict of interest: F. Gagnadoux reports support for the present manuscript from Institut Recherche en Santé Respiratoire des Pays de la Loire to University Hospital of Angers; consulting fees from NYXOAH, SEFAM and RESMED; payment or honoraria for lectures from CIDELEC, ASTEN SANTE and BOEHRINGER INGELHEIM; payment for expert testimony from BOEHRINGER INGELHEIM; support for attending meetings and/or travel from ASTEN SANTE and ACTELION; participation on a Data Safety Monitoring Board or Advisory Board for JAZZ PHARMACEUTICAL; receipt of equipment, materials, drugs, medical writing, gifts or other services from INSPIRE to University Hospital of Angers, outside the present work. ER -